|
1
|
Iwasaki Y, Takaguchi K, Ikeda H, Makino Y,
Araki Y, Ando M, Kobashi H, Kobatake T, Tanaka R, Tomita M, et al:
Risk factors for hepatocellular carcinoma in hepatitis C patients
with sustained virologic response to interferon therapy. Liver Int.
24:603–610. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Enokimura N, Shiraki K, Kawakita T, Saitou
Y, Inoue H, Okano H, Yamamoto N, Deguchi M, Sakai T, Ohmori S, et
al: Hepatocellular carcinoma development in sustained viral
responders to interferon therapy in patients with chronic hepatitis
C. Anticancer Res. 23:593–596. 2003.PubMed/NCBI
|
|
3
|
Okanoue T, Itoh Y, Minami M, Sakamoto S,
Yasui K, Sakamoto M, Nishioji K, Murakami Y and Kashima K:
Interferon therapy lowers the rate of progression to hepatocellular
carcinoma in chronic hepatitis C but not significantly in an
advanced stage: A retrospective study in 1148 patients. Viral
hepatitis therapy study group. J Hepatol. 30:653–659. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoshida H, Shiratori Y, Moriyama M,
Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, et
al: Interferon therapy reduces the risk for hepatocellular
carcinoma: National surveillance program of cirrhotic and
noncirrhotic patients with chronic hepatitis C in Japan. IHIT study
group. Inhibition of hepatocarcinogenesis by interferon therapy.
Ann Intern Med. 131:174–181. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Asahina Y, Tsuchiya K, Tamaki N, Hirayama
I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda K, Kuzuya T, et al:
Effect of aging on risk for hepatocellular carcinoma in chronic
hepatitis C virus infection. Hepatology. 52:518–527. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shindo M, Hamada K, Oda Y and Okuno T:
Long-term follow-up study of sustained biochemical responders with
interferon therapy. Hepatology. 33:1299–1302. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takimoto M, Ohkoshi S, Ichida T, Takeda Y,
Nomoto M, Asakura H, Naito A, Mori S, Hata K, Igarashi K, et al:
Interferon inhibits progression of liver fibrosis and reduces the
risk of hepatocarcinogenesis in patients with chronic hepatitis C:
A retrospective multicenter analysis of 652 patients. Dig Dis Sci.
47:170–176. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tanaka H, Tsukuma H, Kasahara A, Hayashi
N, Yoshihara H, Masuzawa M, Kanda T, Kashiwagi T, Inoue A, Kato M,
et al: Effect of interferon therapy on the incidence of
hepatocellular carcinoma and mortality of patients with chronic
hepatitis C: A retrospective cohort study of 738 patients. Int J
Cancer. 87:741–749. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hiramatsu N, Oze T and Takehara T:
Suppression of hepatocellular carcinoma development in hepatitis C
patients given interferon-based antiviral therapy. Hepatol Res.
45:152–161. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shiratori Y, Imazeki F, Moriyama M, Yano
M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G,
et al: Histologic improvement of fibrosis in patients with
hepatitis C who have sustained response to interferon therapy. Ann
Intern Med. 132:517–524. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nirei K, Kanda T, Nakamura H, Matsuoka S,
Takayama T, Sugitani M and Moriyama M: Persistent hepatic
inflammation plays a role in hepatocellular carcinoma after
sustained virological response in patients with HCV infection. Int
J Med Sci. 15:466–474. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Motoyama H, Tamori A, Kubo S,
Uchida-Kobayashi S, Takemura S, Tanaka S, Ohfuji S, Teranishi Y,
Kozuka R, Kawamura E, et al: Stagnation of histopathological
improvement is a predictor of hepatocellular carcinoma development
after hepatitis C virus eradication. PLoS One. 13:e01941632018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rehermann B, Chang KM, McHutchison JG,
Kokka R, Houghton M and Chisari FV: Quantitative analysis of the
peripheral blood cytotoxic T lymphocyte response in patients with
chronic hepatitis C virus infection. J Clin Invest. 98:1432–1440.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang KM, Thimme R, Melpolder JJ, Oldach
D, Pemberton J, Moorhead-Loudis J, McHutchison JG, Alter HJ and
Chisari FV: Differential CD4(+) and CD8(+) T-cell responsiveness in
hepatitis C virus infection. Hepatology. 33:267–276. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aslan N, Yurdaydin C, Wiegand J, Greten T,
Ciner A, Meyer MF, Heiken H, Kuhlmann B, Kaiser T, Bozkaya H, et
al: Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat.
13:505–514. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
R-Viso AT, Duarte MI, Pagliari C,
Fernandes ER, Brasil RA, Benard G, Romano CC, Ogusuku S, Cavalheiro
NP, Melo CE and Barone AA: Tissue and serum immune response in
chronic hepatitis C with mild histological lesions. Mem Inst
Oswaldo Cruz. 105:25–32. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dimitropoulou D, Karakantza M, Tsamandas
AC, Mouzaki A, Theodorou G and Gogos CA: T-lymphocyte subsets in
peripheral blood and liver tissue of patients with chronic
hepatitis B and C. In Vivo. 25:833–840. 2011.PubMed/NCBI
|
|
18
|
Kretschmer K, Apostolou I, Hawiger D,
Khazaie K, Nussenzweig MC and von Boehmer H: Inducing and expanding
regulatory T cell populations by foreign antigen. Nat Immunol.
6:1219–1227. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kobayashi N, Hiraoka N, Yamagami W, Ojima
H, Kanai Y, Kosuge T, Nakajima A and Hirohashi S: FOXP3+
regulatory T cells affect the development and progression of
hepatocarcinogenesis. Clin Cancer Res. 13:902–911. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakaguchi S, Yamaguchi T, Nomura T and Ono
M: Regulatory T cells and immune tolerance. Cell. 133:775–787.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sakaki M, Hiroishi K, Baba T, Ito T,
Hirayama Y, Saito K, Tonoike T, Kushima M and Imawari M:
Intrahepatic status of regulatory T cells in autoimmune liver
diseases and chronic viral hepatitis. Hepatol Res. 38:354–361.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ward SM, Fox BC, Brown PJ, Worthington J,
Fox SB, Chapman RW, Fleming KA, Banham AH and Klenerman P:
Quantification and localisation of FOXP3+ T lymphocytes
and relation to hepatic inflammation during chronic HCV infection.
J Hepatol. 47:316–324. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fausto N, Mead JE, Gruppuso PA and Braun
L: TGF-beta in liver development, regeneration, and carcinogenesis.
Ann N Y Acad Sci. 593:231–242. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Desmet VJ, Gerber M, Hoofnagle JH, Manns M
and Scheuer PJ: Classification of chronic hepatitis: Diagnosis,
grading and staging. Hepatology. 19:1513–1520. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Knodell RG, Ishak KG, Black WC, Chen TS,
Craig R, Kaplowitz N, Kiernan TW and Wollman J: Formulation and
application of a numerical scoring system for assessing
histological activity in asymptomatic chronic active hepatitis.
Hepatology. 1:431–435. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ishak K, Baptista A, Bianchi L, Callea F,
De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, et al:
Histological grading and staging of chronic hepatitis. J Hepatol.
22:696–699. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vallet-Pichard A, Mallet V, Nalpas B,
Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H and Pol S:
FIB-4: An inexpensive and accurate marker of fibrosis in HCV
infection. comparison with liver biopsy and fibrotest. Hepatology.
46:32–36. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schvarcz R, Glaumann H, Weiland O,
Norkrans G, Wejstål R and Fryden A: Histological outcome in
interferon alpha-2b treated patients with chronic posttransfusion
non-A, non-B hepatitis. Liver. 11:30–38. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Terada M, Ikegami F, Oota M, Ooyama T,
Sezai S, Ito M, Sakurai Y, Kamisaka K, Abe T, Takasu S and Tanaka
Y: A long-term histological prognosis after IFN therapy for chronic
hepatitis C. Nihon Shokakibyo Gakkai Zasshi. 94:163–171. 1997.(In
Japanese). PubMed/NCBI
|
|
30
|
George SL, Bacon BR, Brunt EM,
Mihindukulasuriya KL, Hoffmann J and Di Bisceglie AM: Clinical,
virologic, histologic, and biochemical outcomes after successful
HCV therapy: A 5-year follow-up of 150 patients. Hepatology.
49:729–738. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide
T, Yatsuhashi H and Watanabe H: Clinical features of hepatocellular
carcinoma that occur after sustained virological response to
interferon for chronic hepatitis C. J Gastroenterol Hepatol.
21:122–128. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tajimi M, Ugajin T, Ota M, Hiroishi K,
Nakamura I and Imawari M: Immune responses of liver-infiltrating
lymphocytes and peripheral blood mononuclear cells to hepatitis C
virus core and NS3 antigens. Hepatol Res. 35:250–255. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Colombat M, Charlotte F, Ratziu V and
Poynard T: Portal lymphocytic infiltrate in alcoholic liver
disease. Hum Pathol. 33:1170–1174. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brunt EM, Kleiner DE, Wilson LA, Unalp A,
Behling CE, Lavine JE and Neuschwander-Tetri BA; NASH Clinical
Research NetworkA list of members of the Nonalcoholic
Steatohepatitis Clinical Research Network can be found in the
Appendix, : Portal chronic inflammation in nonalcoholic fatty liver
disease (NAFLD): A histologic marker of advanced
NAFLD-Clinicopathologic correlations from the nonalcoholic
steatohepatitis clinical research network. Hepatology. 49:809–820.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yeh MM and Brunt EM: Pathological features
of fatty liver disease. Gastroenterology. 147:754–764. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rakha EA, Adamson L, Bell E, Neal K, Ryder
SD, Kaye PV and Aithal GP: Portal inflammation is associated with
advanced histological changes in alcoholic and non-alcoholic fatty
liver disease. J Clin Pathol. 63:790–795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hayflick L and Moorhead PS: The serial
cultivation of human diploid cell strains. Exp Cell Res.
25:585–621. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rodier F and Campisi J: Four faces of
cellular senescence. J Cell Biol. 192:547–556. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lujambio A, Akkari L, Simon J, Grace D,
Tschaharganeh DF, Bolden JE, Zhao Z, Thapar V, Joyce JA,
Krizhanovsky V and Lowe SW: Non-cell-autonomous tumor suppression
by p53. Cell. 153:449–460. 2013. View Article : Google Scholar : PubMed/NCBI
|
